Description

Ritonavir is a peptidomimetic HIV?1 protease inhibitor frequently used in research to explore viral enzyme kinetics, protease inhibition, and drug?drug interaction mechanisms. It is also commonly used as a pharmacokinetic booster in combination antiviral protocols.

Manufactured by Fujian Guangsheng Pharmaceutical Co., Ltd., these tablets comply with regulatory standards under approval number H20254135. Though the packaging barcode is pending, the product is intended for laboratory research rather than therapeutic use.

Product Specifications

Mechanism of Action & Research Applications

Ritonavir binds and inhibits the HIV?1 protease enzyme, blocking the cleavage of viral polyproteins and impairing viral maturation. In research, Ritonavir Tablets (Fushengtang) are used to study:

• HIV protease inhibition kinetics

• Drug-drug interactions in combination regimens

• Pharmacokinetic boosting effects on co-administered antivirals

• Resistance mechanisms and in vitro antiviral assays

Its high potency and specific mechanism make it ideal for controlled laboratory or preclinical pharmacological investigations.

Side Effects (For Reference Only in Models)

In research or animal models, Ritonavir Tablets (Fushengtang) may induce:

• Altered lipid profiles (e.g. hypertriglyceridemia)

• Gastrointestinal disturbances (nausea, diarrhea)

• Liver enzyme elevations (e.g. ALT/AST)

• Insulin resistance or glucose intolerance

• Potential drug interactions due to CYP3A inhibition

These effects are observational in controlled models and provided for research safety reference only.

Disclaimer

Ritonavir Tablets (Fushengtang) are supplied strictly for laboratory research use only and are not approved for human or veterinary clinical use. All handling and usage should comply with institutional and local biosafety regulations.